446 related articles for article (PubMed ID: 21844037)
1. The European Medicines Agency: an overview of its mission, responsibilities, and recent initiatives in cancer drug regulation.
Pignatti F; Gravanis I; Herold R; Vamvakas S; Jonsson B; Marty M
Clin Cancer Res; 2011 Aug; 17(16):5220-5. PubMed ID: 21844037
[TBL] [Abstract][Full Text] [Related]
2. The European Medicines Agency: a public health European agency?
Mahalatchimy A; Rial-Sebbag E; De Grove-Valdeyron N; Tournay V; Cambon-Thomsen A; Duguet AM; Taboulet F
Med Law; 2012 Mar; 31(1):25-42. PubMed ID: 22908736
[TBL] [Abstract][Full Text] [Related]
3. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
[TBL] [Abstract][Full Text] [Related]
4. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
5. Top adviser at the European Medicines Agency quits suddenly.
Benkimoun P
BMJ; 2012 Apr; 344():e2641. PubMed ID: 22496308
[No Abstract] [Full Text] [Related]
6. Regulating medicines in Europe: the European Medicines Agency, marketing authorisation, transparency and pharmacovigilance.
Permanand G; Mossialos E; McKee M
Clin Med (Lond); 2006; 6(1):87-90. PubMed ID: 16521363
[TBL] [Abstract][Full Text] [Related]
7. [European registration of medicines: pros and cons for prescriber and patient].
Offerhaus L
Ned Tijdschr Geneeskd; 1997 May; 141(21):1028-33. PubMed ID: 9340558
[TBL] [Abstract][Full Text] [Related]
8. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
Tomić S; Sucić AF; Martinac AI
Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
[TBL] [Abstract][Full Text] [Related]
9. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
10. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
[TBL] [Abstract][Full Text] [Related]
11. Switzerland: one year's experience with new regulations and a new agency.
Voelksen R
Med Device Technol; 2003 Mar; 14(2):28-9. PubMed ID: 12698697
[TBL] [Abstract][Full Text] [Related]
12. [Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].
Enzmann H; Broich K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):120-8. PubMed ID: 23663906
[TBL] [Abstract][Full Text] [Related]
13. Will children with cancer benefit from the new European Paediatric Medicines Regulation?
Vassal G
Eur J Cancer; 2009 Jun; 45(9):1535-46. PubMed ID: 19419857
[TBL] [Abstract][Full Text] [Related]
14. The innovative medicines initiative: a European response to the innovation challenge.
Goldman M
Clin Pharmacol Ther; 2012 Mar; 91(3):418-25. PubMed ID: 22318619
[TBL] [Abstract][Full Text] [Related]
15. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
Senderowicz AM; Pfaff O
Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
[TBL] [Abstract][Full Text] [Related]
16. Provision of information on regulatory authorities' websites.
Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
[TBL] [Abstract][Full Text] [Related]
17. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
18. The role of the Therapeutic Goods Administration and the Medicine and Medical Devices Safety Authority in evaluating complementary and alternative medicines in Australia and New Zealand.
Ghosh D; Skinner M; Ferguson LR
Toxicology; 2006 Apr; 221(1):88-94. PubMed ID: 16481089
[TBL] [Abstract][Full Text] [Related]
19. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
20. Drug development in oncology: a regulatory perspective.
Augustus S
Am J Ther; 2011 Jul; 18(4):323-31. PubMed ID: 20335790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
